OR WAIT null SECS
January 31, 2017
China is proposing to make more than 300 new and traditional drugs affordable to mass market consumers, Reuters reported Thursday. Changes to the National Reimbursement Drug List (NRDL) are set to include GlaxoSmithKline's hepatitis drug Viread, AstraZeneca's heart drug Brilinta and Sanofi's chronic kidney disease drug Renvela, with oncology drugs also likely to be added. Most additions to the list will be traditional Chinese medicines, but about 130 are expected to be modern drugs. See the Reuters story here.